Business Wire · Feb 2026
Announced major enhancements to DiffuseSandbox and RamaX, enabling design of up to 10,000 sequences and screening against up to 100 antigens in parallel, with 1-2 week binder discovery turnaround.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Diffuse Bio is a San Carlos, California biotech building generative AI and experimental platforms for protein design, with a self-serve design app and linked wet-lab screening workflow for engineering protein therapeutics, diagnostics, and enzymes.
Primary product
DiffuseSandbox, the self-serve AI protein design platform integrated with RamaX screening
Founded
2022
Headquarters
San Carlos, California, United States
Team size
10-20
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Generative AI for protein design / AI drug discovery
Offices
0 jobs at Diffuse Bio
Check back later for new openings
Business model
Stage
early-stage VC / seed
Total raised
$500K
Latest round
Early Stage VC · Mar 2024
Mar 2024
Sep 2023 · Fellows Fund
Jan 2023 · Y Combinator
Jan 2023 · Y Combinator
Investors
Mission-driven, interdisciplinary team of scientists, machine learning researchers, and engineers focused on rapid experimentation and bridging AI research with biological reality through in-house assay development and data generation.
Work style
Flexible
Visa sponsorship
Limited
Compensation
Public job posting shows a Software Engineer salary range of $90K-$130K plus 0.05%-0.60% equity; Bay Area preferred, remote possible for exceptional candidates; US citizens or visa holders only.
Pricing
Free-starting-credits self-serve platform with quote-based screening and partnership/custom development pricing
Differentiators
Technology
Customers
Estimated monthly visits
4.4K
Business Wire · Feb 2026
Announced major enhancements to DiffuseSandbox and RamaX, enabling design of up to 10,000 sequences and screening against up to 100 antigens in parallel, with 1-2 week binder discovery turnaround.
Business Wire · Jun 2025
Public launch of DSG2-mini in DiffuseSandbox, the first time researchers could directly access Diffuse Bio's protein design capability through the web platform.
LinkedIn · Jun 2024
Namrata Anand shared DSG-1 results showing ~3% binder hit rate, strong sub-10nM binders, and the team's progression toward a foundation model for protein design.
NBC (local syndication) · Mar 2023
Interview coverage featuring Namrata Anand discussing Diffuse Bio's mission to use AI to speed up protein and drug development.
The New York Times · Jan 2023
High-profile coverage of AI protein design that helped spotlight the broader technical area Diffuse Bio operates in.